Adjunct PIs
- Kaan Boztug (Director LBI-RUD)
- Thijn Brummelkamp (CeMM)
- Georg Busslinger Group (CeMM)
- Robert Kralovics Group (CeMM)
- Joanna I. Loizou Group (CeMM)
- Nuno Maulide (CeMM)
- Jörg Menche (CeMM)
- Vanja Nagy (LBI-RUD)
- Thomas Reiberger (LBI-RUD/CeMM)
- Georg Stary (LBI-RUD/CeMM)
- Davide Seruggia (CCRI/CeMM)
- Miriam Unterlass (CeMM)
- Andreas Villunger (CeMM/LBI-RUD)
| Year | Paper |
|---|---|
| 2020 | Balligand T, Achouri Y, Pecquet C, Gaudray G, Colau D, Hug E, Rahmani Y, Stroobant V, Plo I, Vainchenker W, Kralovics R, Van den Eynde BJ, Defour JP, Constantinescu SN. Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. Leukemia. 2020 Feb;34(2):510-521. doi: 10.1038/s41375-019-0538-1. Epub 2019 Aug 30. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31471561 |
| 2020 | Jia R, Kralovics R. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions. Int J Hematol. 2020 Feb;111(2):182-191. doi: 10.1007/s12185-019-02778-9. Epub 2019 Nov 18. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31741139 |
| 2020 | Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non- inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31. Erratum in: Lancet Haematol. 2020 Feb 25. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/32014125 |
| 2020 | Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R. High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica. 2020 Jan 31;105(2):435-447. doi: 10.3324/haematol.2019.216986. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31123029 |
| 2019 | Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F, Schwarz J,Wojtaszewska M, Palmqvist L, Akiki S, Aggerholm A, Tolstrup Andersen M, GirodonF, Kjær L, Oppliger Leibundgut E, Pancrazzi A, Vorland M, Andrikovics H,Kralovics R, Cassinat B, Coucelo M, Eftimov A, Haslam K, Kusec R, Link-LenczowskaD, Lodé L, Matiakowska K, Naguib D, Navaglia F, Novotny GW, Percy MJ, SudarikovA, Hermouet S, Pallisgaard N. International external quality assurance of JAK2V617F quantification. Ann Hematol. 2019 May;98(5):1111-1118. doi:10.1007/s00277-018-3570-8. Epub 2018 Dec 8. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30535576 |
| 2019 | Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T,Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O,Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, ProchazkovaJ, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A,Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L,Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R. High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.Haematologica. 2019 May 23. pii: haematol.2019.216986. doi:10.3324/haematol.2019.216986. [Epub ahead of print] Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31123029 |
| 2019 | Pecquet C, Chachoua I, Roy A, Balligand T, Vertenoeil G, Leroy E, Albu RI,Defour JP, Nivarthi H, Hug E, Xu E, Ould-Amer Y, Mouton C, Colau D, Vertommen D, Shwe MM, Marty C, Plo I, Vainchenker W, Kralovics R, Constantinescu SN. Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Blood. 2019 Jun 20;133(25):2669-2681. doi:10.1182/blood-2018-09-874578. Epub 2019 Mar 22. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30902807 |
| 2019 | Schischlik F, Jäger R, Rosebrock F, Hug E, Schuster M, Holly R, Fuchs E,Milosevic Feenstra JD, Bogner E, Gisslinger B, Schalling M, Rumi E, Pietra D,Fischer G, Faé I, Vulliard L, Menche J, Haferlach T, Meggendorfer M, Stengel A,Bock C, Cazzola M, Gisslinger H, Kralovics R. Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood. 2019 Jul 11;134(2):199-210. doi: 10.1182/blood.2019000519. Epub2019 May 7. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31064751 |
| 2019 | Sdelci S, Rendeiro AF, Rathert P, You W, Lin JG, Ringler A, Hofstätter G,Moll HP, Gürtl B, Farlik M, Schick S, Klepsch F, Oldach M, Buphamalai P,Schischlik F, Májek P, Parapatics K, Schmidl C, Schuster M, Penz T, Buckley DL,Hudecz O, Imre R, Wang SY, Maric HM, Kralovics R, Bennett KL, Müller AC, MechtlerK, Menche J, Bradner JE, Winter GE, Klavins K, Casanova E, Bock C, Zuber J,Kubicek S. MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nat Genet. 2019 Jun;51(6):990-998. doi:10.1038/s41588-019-0413-z. Epub 2019 May 27. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31133746 |
| 2019 | Balligand T, Achouri Y, Pecquet C, Gaudray G, Colau D, Hug E, Rahmani Y, Stroobant V, Plo I, Vainchenker W, Kralovics R, Van den Eynde BJ, Defour JP, Constantinescu SN. Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. Leukemia. 2019 Aug 30. doi: 10.1038/s41375-019-0538-1. Abstract: https://pubmed.ncbi.nlm.nih.gov/31471561/ |
| 2019 | Jia R, Kralovics R. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions. Int J Hematol. 2019 Nov 18. doi: 10.1007/s12185-019-02778-9. Abstract: https://pubmed.ncbi.nlm.nih.gov/31741139/ |
| 2019 | Muller A, Gasch J, Albring KF, Aberger F, Nivarthi H, Khemeri M, Moriggl R, Friedrich KH. Interplay of transcription factors STAT3, STAT1 and AP-1 mediates activity of the matrix metallo-proteinase-1 promoter in colorectal carcinoma cells. Neoplasma. 2019 May 23;66(3):357-366. doi: 10.4149/neo_2018_180731N560. Abstract: https://pubmed.ncbi.nlm.nih.gov/30569725/ |
| 2019 | Unterleuthner D, Neuhold P, Schwarz K, Janker L, Neuditschko B, Nivarthi H, Crncec I, Kramer N, Unger C, Hengstschläger M, Eferl R, Moriggl R, Sommergruber W, Gerner C, Dolznig H. Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. Angiogenesis. 2019 Oct 30. doi: 10.1007/s10456-019-09688-8. Abstract: https://pubmed.ncbi.nlm.nih.gov/31667643/ |
| 2019 | Uras IZ, Maurer B, Nivarthi H, Jodl P, Kollmann K, Prchal-Murphy M, Milosevic Feenstra JD, Zojer M, Lagger S, Grausenburger R, Grabner B, Holly R, Kavirayani A, Bock C, Gisslinger H, Valent P, Kralovics R, Sexl V. CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks. Blood. 2019;133(15):1677–1690. doi:10.1182/blood-2018-08-872648 Abstract: https://pubmed.ncbi.nlm.nih.gov/30635286/ |
| 2018 | Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, Ghelli Luserna di Rorá A, Padella A, Solli V, Franchini E, Ottaviani E, Ferrari A, Baldazzi C, Testoni N, Iacobucci I, Soverini S, Haferlach T, Guadagnuolo V, Semerad L, Doubek M, Steurer M, Racil Z, Paolini S, Manfrini M, Cavo M, Simonetti G, Kralovics R, Martinelli G. Chromothripsis in acute myeloid leukemia: biological features and impact on survival. Leukemia. 2018 Feb 23. doi: 10.1038/s41375-018-0035-y. [Epub ahead of print] Abstract: https://www.ncbi.nlm.nih.gov/pubmed/29472722 |
| 2018 | Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/JCI94509. Epub 2017 Dec 4. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/29200404 |
| 2018 | Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S, Doubek M. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2018 Feb;32(2):450-461. doi: 10.1038/leu.2017.230. Epub 2017 Jul 24. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28744014 |
| 2018 | Bigenzahn JW, Collu GM, Kartnig F, Pieraks M, Vladimer GI, Heinz LX, Sedlyarov V, Schischlik F, Fauster A, Rebsamen M, Parapatics K, Blomen VA, Müller AC, Winter GE, Kralovics R, Brummelkamp TR, Mlodzik M, Superti-Furga G. LZTR1 is a regulator of RAS ubiquitination and signaling. Science. 2018 Nov 15. pii: eaap8210. doi: 10.1126/science.aap8210. [Epub ahead of print] Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30442766 |
| 2018 | Javaheri T, Kazemi Z, Jan Pencik, Pham HTT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DNT, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R. Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. Cell Death Dis. 2018 Jul 23;9(8):800. doi: 10.1038/s41419-018-0773-9. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30038364 |
| 2018 | Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knösel T, Kenner L, Freund P, Aberger F, Han X, Kralovics R, Dolznig H, Jennek S, Friedrich K, Moriggl R. Correction: The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. Oncotarget. 2018 Sep 18;9(73):33865. doi: 10.18632/oncotarget.26156. eCollection 2018 Sep 18. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30333916 |
| 2018 | Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/29907599 |
| 2018 | Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30287855 |
| 2017 | Moder M, Velimezi G, Owusu M, Mazouzi A, Wiedner M, Ferreira da Silva J, Robinson-Garcia L, Schischlik F, Slavkovsky R, Kralovics R, Schuster M, Bock C, Ideker T, Jackson SP, Menche J, Loizou JI. Parallel genome-wide screens identify synthetic viable interactions between the BLM helicase complex and Fanconi anemia. Nat Commun. 2017 Nov 1;8(1):1238. doi: 10.1038/s41467-017-01439-x. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/29089570 |
| 2017 | Schischlik F, Kralovics R. Mutations in myeloproliferative neoplasms - their significance and clinical use. Expert Rev Hematol. 2017 Nov;10(11):961-973. doi: 10.1080/17474086.2017.1380515. Epub 2017 Sep 25. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28914569 |
| 2017 | Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S, Doubek M. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.230. [Epub ahead of print] Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28744014 |
| 2016 | Buxhofer-Ausch V, Gisslinger B, Schalling M, Gleiss A, Schiefer AI, Müllauer L, Thiele J, Kralovics R, Gisslinger H. Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. Br J Haematol. 2016 Jul 19. doi: 10.1111/bjh.14202. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27432009 |
| 2016 | Kapralova K, Horvathova M, Pecquet C, Fialova Kucerova J, Pospisilova D, Leroy E, Kralova B, Milosevic Feenstra JD, Schischlik F, Kralovics R, Constantinescu SN, Divoky V. Cooperation of germline JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia. Blood. 2016 Jul 7. pii: blood-2016-02-698951. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27389715 |
| 2016 | Kornienko AE, Dotter CP, Guenzl PM, Gisslinger H, Gisslinger B, Cleary C, Kralovics R, Pauler FM, Barlow DP. Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans. Genome Biol. 2016 Jan 29;17(1):14. doi: 10.1186/s13059-016-0873-8. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26821746 |
| 2016 | Nivarthi H, Chen D, Cleary C, Kubesova B, Jäger R, Bogner E, Marty C, Pecquet C, Vainchenker W, Constantinescu SN, Kralovics R. Thrombopoietin receptor is required for the oncogenic function of CALR mutants. Leukemia. 2016 Feb 17. doi: 10.1038/leu.2016.32. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26883579 |
| 2016 | Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knösel T, Kenner L, Freund P, Aberger F, Han X, Kralovics R, Dolznig H, Jennek S, Friedrich K, Moriggl R. The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. Oncotarget. 2016 May 12. doi: 10.18632/oncotarget.9315. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27191495 |
| 2016 | Rumi E, Harutyunyan AS, Pietra D, Feenstra JD, Cavalloni C, Roncoroni E, Casetti I, Bellini M, Milanesi C, Renna MC, Gotti M, Astori C, Kralovics R, Cazzola M. LNK mutations in familial myeloproliferative neoplasms. Blood. 2016 Jul 7;128(1):144-5. doi: 10.1182/blood-2016-04-711150 Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27216218 |
| 2016 | Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Dirnhofer S, Guglielmelli P, Vannucchi AM, Feenstra JD, Kralovics R, Orkin SH, Skoda RC. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016 Jul 25;213(8):1479-96. doi: 10.1084/jem.20151136. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27401344 |
| 2016 | Antic DA, Vukovic VM, Milosevic Feenstra JD, Kralovics R, Bogdanovic AD, Dencic Fekete MS, Mihaljevic BS. 8p11 myeloproliferative syndrome: diagnostic challenges and pitfalls. J BUON. 2016 May-Jun;21(3):745-9. Abstract: https://www.ncbi.nlm.nih.gov/pubmed/27569099 |
| 2016 | Javaheri T, Kazemi Z, Pencik J, Pham HT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DN, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R. Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. Cell Death Dis. 2016 Oct 13;7(10):e2419. doi: 10.1038/cddis.2016.268. Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133963/ |
| 2016 | Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2016 Dec 27. pii: blood-2016-10-695940. doi: 10.1182/blood-2016-10-695940. Abstract: http://www.bloodjournal.org/content/early/2016/12/27/blood-2016-10-695940 |
| 2015 | Harutyunyan AS, Jäger R, Chen D, Berg T, Rumi E, Gisslinger B, Pietra D, Gisslinger H, Cazzola M, Kralovics R. Allelic imbalance in CALR somatic mutagenesis. Leukemia. 2015 Jan 8. doi: 10.1038/leu.2015.3 Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25567134 |
| 2015 | Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015 Apr 7;6:6691. doi: 10.1038/ncomms7691. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25849990 |
| 2015 | Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94. doi: 10.1002/ajh.23928. Epub 2015 Mar 2. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25545244 |
| 2015 | Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu RI, Marty C, Gryshkova V, Defour JP, Vertenoeil G, Ngo A, Koay A, Raslova H, Courtoy PJ, Choong ML, Plo I, Vainchenker W, Kralovics R, Constantinescu SN. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2015 Dec 14. pii: blood-2015-11-681932. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26668133 |
| 2015 | Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26261238 |
| 2015 | Harutyunyan AS, Giambruno R, Krendl C, Stukalov A, Klampfl T, Berg T, Chen D, Milosevic Feenstra JD, Jäger R, Gisslinger B, Gisslinger H, Rumi E, Passamonti F, Pietra D, Müller AC, Parapatics K, Breitwieser FP, Herrmann R, Colinge J, Bennett KL, Superti-Furga G, Cazzola M, Hammond E, Kralovics R. Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood. 2015 Nov 16. pii: blood-2015-09-668673. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26574608 |
| 2015 | Licciardello MP, Müllner MK, Dürnberger G, Kerzendorfer C, Boidol B, Trefzer C, Sdelci S, Berg T, Penz T, Schuster M, Bock C, Kralovics R, Superti-Furga G, Colinge J, Nijman SM, Kubicek S. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene. 2015 Jul;34(29):3780-90. doi: 10.1038/onc.2014.319. Epub 2014 Sep 29. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25263445 |
| 2015 | Marty C, Pecquet C, Nivarthi H, Elkhoury M, Chachoua I, Tulliez M, Villeval JL, Raslova H, Kralovics R, Constantinescu SN, Plo I, Vainchenker W. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2015 Nov 25. pii: blood-2015-11-679571. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26608331 |
| 2015 | Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, Milanesi C, Jäger R, Chen D, Berg T, Schalling M, Schuster M, Bock C, Constantinescu SN, Cazzola M, Kralovics R. Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms. Blood. 2015 Sep 30. pii: blood-2015-07-661835. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26423830 |
| 2015 | Rumi E, Milosevic JD, Selleslag D, Casetti I, Lierman E, Pietra D, Cavalloni C, Bellini M, Milanesi C, Dambruoso I, Astori C, Kralovics R, Vandenberghe P, Cazzola M. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26202607 |
| 2014 | Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C, Berg T, Sant'antonio E, Boveri E, Pascutto C, Astori C, Kralovics R, Cazzola M. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014 Apr 10;123(15):2416-9. doi: 10.1182/blood-2014-01-550434. Epub 2014 Feb 19. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24553179 |
| 2014 | Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 3;123(14):2220-8. doi: 10.1182/blood-2013-11-537167. Epub 2014 Jan 29. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24478400 |
| 2014 | Buxhofer-Ausch V, Olcaydu D, Gisslinger B, Schalling M, Frantal S, Thiele J, Müllauer L, Kvasnicka HM, Watzke H, Kralovics R, Gisslinger H. Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. Eur J Haematol. 2014 Aug;93(2):103-11. doi: 10.1111/ejh.12307. Epub 2014 Apr 23. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24617727 |
| 2014 | Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C, Leroy E, Harutyunyan AS, Abgrall JF, Favier R, Toussaint A, Solary E, Kralovics R, Constantinescu SN, Najman A, Vainchenker W, Plo I, Bellanné-Chantelot C. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014 Feb 27;123(9):1372-83. doi: 10.1182/blood-2013-05-504555. Epub 2014 Jan 7. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24398328 |
| 2014 | Cazzola M, Kralovics R. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med. 2014 Mar 20;370(12):1169. doi: 10.1056/NEJMc1400499. Comment. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24645955 |
| 2014 | Broséus J, Lippert E, Harutyunyan AS, Jeromin S, Zipperer E, Florensa L, Milosevic JD, Haferlach T, Germing U, Luño E, Schnittger S, Kralovics R, Girodon F. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2014 Jun;28(6):1374-6. doi: 10.1038/leu.2014.49. Epub 2014 Jan 30. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24476766 |
| 2014 | Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014 Jun 12;123(24):3714-9. doi: 10.1182/blood-2014-03-530865. Epub 2014 Apr 30. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24786775 |
| 2014 | Jäger R, Harutyunyan AS, Rumi E, Pietra D, Berg T, Olcaydu D, Houlston RS, Cazzola M, Kralovics R. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Am J Hematol. 2014 Sep 5. doi: 10.1002/ajh.23842. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25196853 |
| 2013 | Cleary C, Kralovics R. Molecular basis and clonal evolution of myeloproliferative neoplasms. Clin Chem Lab Med. 2013 Oct 1; 51(10):1889-96. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23729579 |
| 2013 | Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka H-M, Kralovics R, Petrides PE, Gastl G, Gisslinger B, Muellauer L, Schlögl E, Indrak K, Pytlik R, Briere K, Kiladjian JJ, Beykirch M, Gaede B, Griesshammer M, Herbrik-Zipp M, Hurtz HJ, Jacobs G, Jäcki SH, Keilholz U, MezgerJ, Schlag P, Schriever F, Masszi T, Sacchi S, Griniptì R ,Tavoriene I, Dmoszynska A, Hellman A, Jedrzejczak WW, Robak T, SkotnickiA, Goh YT, Cernelc P. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 March 7; 121(10): 1720–1728. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23315161 |
| 2013 | Rommer A, Steinleitner K, Hackl H, Schneckenleithner C, Engelmann M, Scheideler M, Vlatkovic I, Kralovics R, Cerny-Reiterer, Valent P, Sill H, Wieser R. Overexpression of primary microRNA 221/222 in acute myeloid leukemia. BMC Cancer. 2013; 13: 364. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23895238 |
| 2013 | Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, Boni M, Bernasconi P, Passamonti F, Kralovics R, Cazzola M. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013 Jun 10; 31(17):e269-71. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23630205 |
| 2013 | Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24325356 |
| 2013 | Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2013 Dec 23. [Epub ahead of print] Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24366362 |
| 2013 | Gisslinger H, Schalling M, Gisslinger B, Skrabs C, Müllauer L, Kralovics R. Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis. Am J Hematol. 2013 Nov 25. doi: 10.1002/ajh.23637. [Epub ahead of print] Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24273107 |
| 2013 | Them NC, Kralovics R. Genetic Basis of MPN: Beyond JAK2-V617F. Curr Hematol Malig Rep. 2013 Dec;8(4):299-306. doi: 10.1007/s11899-013-0184-z. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24190690 |
| 2012 | Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A. Unraveling the genetic underpinnings of myeloproliferative neoplasm and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012 May;87(5):562-8. doi: 10.1002/ajh.23169. Epub 2012 Mar 28. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22460584 |
| 2012 | Bento C, Maia TM, Milosevic JD, Carreira IM, Kralovics R, Ribeiro ML. Beta thalassemia major due to acquired uniparental disomy in a previously healthy adolescent. Haematologica. 2012 Aug 8. [Epub ahead of print]. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22875618 |
| 2012 | Clarke M, Dumon S, Ward C, Jäger R, Freeman S, Dawood B, Sheriff L, Lorvellec M, Kralovics R, Frampton J, García P. MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia. Leukemia. 2012 Aug 22. doi: 10.1038/leu.2012.241. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22910183 |
| 2012 | Harutyunyan AS, Kralovics R. Role of germline genetic factors in MPN pathogenesis. Hematol Oncol Clin North Am. 2012 Oct;26(5):1037-51. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23009936 |
| 2012 | Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol. 2012 Dec 12. [Epub ahead of print]. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23233154 |
| 2012 | Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A, Klampfl T, Harutyunyan AS, Gisslinger H, Gisslinger B, Burjanivova T, Rumi E, Pietra D, Elena C, Vannucchi AM, Doubek M, Dvorakova D, Robesova B, Wieser R, Koller E, Suvajdzic N, Tomin D, Tosic N, Colinge J, Racil Z, Steurer M, Pavlovic S, Cazzola M, Kralovics R. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012 Nov;87(11):1010-6. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22887079 |
| 2012 | Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, Gisslinger B, Rumi E, Pietra D, Malcovati L, Elena C, Doubek M, Steurer M, Tosic N, Pavlovic S, Guglielmelli P, Pieri L, Vannucchi AM, Gisslinger H, Cazzola M, Kralovics R. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol. 2012 Mar;87(3):245-50. doi: 10.1002/ajh.22257. Epub 2011 Dec 21. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22190018 |
| 2011 | Carillo S, Henry L, Lippert E, Girodon F, Guiraud I, Richard C, Dubois Galopin F, Cleyrat C, Jourdan E, Kralovics R, Hermouet S, Lavabre-Bertrand T. Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations – clinical relevance in the monitoring of polycythemia. J Mol Diagn. 2011 May;13(3):263-70. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21497288 |
| 2011 | Harutyunyan A, Gisslinger B, Klampfl T, Berg T, Bagienski K, Gisslinger H, Kralovics R. Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies. Leukemia. 2011 Nov;25(11):1782-4. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21681190 |
| 2011 | Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011 Feb 3;364(5):488-90. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21288114 |
| 2011 | Huang R, Jaritz M, Guenzl P, Vlatkovic I, Sommer A, Tamir IM, Marks H, Klampfl T, Kralovics R, Stunnenberg HG, Barlow DP, Pauler FM. An RNA-Seq strategy to detect the complete coding and non-coding transcriptome including full-length imprinted macro ncRNAs. PLoS One. 2011;6(11):e27288. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22102886 |
| 2011 | Jager R, Kralovics R. Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms. Curr Cancer Drug Targets. 2011 Jan;11(1):20-30. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21062246 |
| 2011 | Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, Olcaydu D, Passamonti F, Rumi E, Pietra D, Jager R, Pieri L, Guglielmelli P, Iacobucci I, Martinelli G, Cazzola M, Vannucchi AM, Gisslinger H, Kralovics R. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011 Jul 7;118(1):167-76. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21531982 |
| 2011 | Olcaydu D, Rumi E, Harutyunyan A, Passamonti F, Pietra D, Pascutto C, Berg T, Jager R, Hammond E, Cazzola M, Kralovics R. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2011 Mar;96(3):367-74. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21173100 |
| 2011 | Rumi E, Harutyunyan A, Elena C, Pietra D, Klampfl T, Bagienski K, Berg T, Casetti I, Pascutto C, Passamonti F, Kralovics R, Cazzola M. Identification of genomic aberrations associated with disease transformation by means of highresolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol. 2011 Dec;86(12): 974-9. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21953568 |
| 2011 | Vilaine M, Olcaydu D, Harutyunyan A, Bergeman J, Tiab M, Ramee JF, Chen JM, Kralovics R, Hermouet S. Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm. Blood. 2011 Dec 8;118(24):6468-70. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22161852 |
| 2011 | Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N, Wolf E, Seppi K, Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki T, Hotzy C, Reinthaler E, Harutyunyan A, Kralovics R, Peters A, Zimprich F, Brucke T, Poewe W, Auff E, Trenkwalder C, Rost B, Ransmayr G, Winkelmann J, Meitinger T, Strom TM. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011 Jul 15;89(1):168-75. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21763483 |
| 2010 | Jager R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B, Pietra D, Harutyunyan A, Klampfl T, Olcaydu D, Cazzola M, Kralovics R. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia. 2010 Jul;24(7):1290-8. Epub 2010 May 27. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20508609 |
| 2010 | Jager R, Kralovics R. Molecular basis and clonal evolution of myeloproliferative neoplasms. Haematologica. 2010 Apr;95(4):526-9. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20378573 |
| 2010 | Jager R, Kralovics R. Molecular pathogenesis of Philadelphia chromosome-negative chronic myeloproliferative neoplasms. Curr Cancer Drug Targets. 2010 Nov 10. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21062246 |
| 2009 | Buxhofer-Ausch V, Gisslinger H, Berg T, Gisslinger B, Kralovics R. Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofifibrosis. Eur J Haematol, 2009 Feb;82(2):161-3. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19018861 |
| 2009 | Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nature Genetics, 2009 41(4):450-4. Epub 2009 Mar 15. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19287385 |
| 2009 | Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D, Passamonti F, Lippert E, Carillo S, Girodon F, Vannucchi A, Reading NS, Prchal JT Ay C, Pabinger I, Gisslinger H, Kralovics R. The GGCC haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation positive polycythemia vera. Leukemia, 2009 Oct;23(10):1924-6. Epub 2009 May 14. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19440215 |
| 2009 | Schaub FX, Jäger R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood, 2009 Feb;113(9):2022-7. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19047681 |
| 2008 | Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008 Oct;22(10):1841–8. Review. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18754034 |
| 2008 | Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008, 111: 3863–3866. (abstract) Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18195094 |
| 2008 | Liu K, Kralovics R, Rudzki Z, Grabowska B, Buser AS, Olcaydu D, Gisslinger H, Tiedt R, Frank P, Okon K, Van der Maas APC and Skoda RC. A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica 2008, 93(5); 706–14. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18367486 |
| 2008 | Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ, Bilban M, Esterbauer H, Krauth MT, Sperr WR, Longley JB, Kralovics R, Moriggl R, Zappulla J, Liblau RS, Schwarzinger I, Sexl V, Sillaber C, Valent P. Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens. The Journal of Immunology, 2008, 180: 5466–5476. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18390729 |
| 2008 | Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L, Skoda R, Cazzola M. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008, 111:1686–1689. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/17984312 |